13. 多発性硬化症/視神経脊髄炎
[臨床試験数:3,050,薬物数:2,147(DrugBank:348),標的遺伝子数:244,標的パスウェイ数:228

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-003147-19-GR
(EUCTR)
18/07/201625/05/2016To confirm the safety and efficacy of NEUROASPIS PLP10® in the treatment of individuals, who have been diagnosed with relapsing remitting multiple sclerosis (MS).Novel Oral Nutraceutical Intervention NEUROASPIS PLP10® for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Multicenter, Parallel-group, Phase III, Double-blind, Randomized, Placebo-Controlled, Add-on with Interferon Beta, Trial of Efficacy and Safety. - Efficacy and Safety study of NEUROASPIS PLP10® versus placebo Relapsing-Remitting Multiple Sclerosis (RRMS)
MedDRA version: 19.0;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: NEUROASPIS PLP10®
INN or Proposed INN: FISH OIL,RICH IN OMEGA 3 ACIDS
Other descriptive name: FISH OIL, RICH IN OMEGA-3-ACIDS
INN or Proposed INN: BORAGE OIL 20% GLA
Other descriptive name: BORAGE OIL
INN or Proposed INN: beta-Carotene
Other descriptive name: BETACAROTENE
INN or Proposed INN: Gamma-tocopherol
PALUPA Medical LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
220Phase 3Greece
2NCT02133664
(ClinicalTrials.gov)
June 20146/5/2014Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple SclerosisLipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple SclerosisMultiple Sclerosis;CognitionDrug: lipoic acid and omega-3 fatty acids;Drug: PlaceboOregon Health and Science UniversityNational Multiple Sclerosis SocietyCompleted18 Years65 YearsAll54Phase 1;Phase 2United States
3NCT00360906
(ClinicalTrials.gov)
December 20044/8/2006Omega-3 Fatty Acid Treatment in Multiple SclerosisOmega-3 Fatty Acid Treatment in Multiple SclerosisRelapsing-Remitting Multiple SclerosisDrug: Triomar™ (omega-3 fatty acids)Haukeland University HospitalThe Multiple Sclerosis National Competence Centre;The Norwegian Multiple sclerosis Society;Pronova BioPharma;Serono Nordic;Amersham HealthCompleted18 Years55 YearsBoth100Phase 2;Phase 3Norway